Eplerenone Observational Study Of Safety And Efficacy Evaluation To Normalize Blood Pressure For Clinical Effectiveness
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 3,338
- 主要终点
- Number of Participants With Treatment Related Adverse Events.
研究概览
简要总结
To collect the efficacy and safety information of Eplerenone on patients with hypertension related to their appropriate use in daily practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or Female patients who are prescribed Selara tablet for Hypertension.
排除标准
- •Subjects who have been prescribed Selara tablet.
研究组 & 干预措施
Eplerenone
Subjects who are treated with Eplerenone tablet for hypertension disease
干预措施: Selara (Drug)
结局指标
主要结局
Number of Participants With Treatment Related Adverse Events.
时间窗: 12 weeks
Adverse events mean all unfavorable events that occur in participants after administration of Selara, irrespective of causal relationship to Selara (including clinically problematic abnormal changes in laboratory test values). Treatment Related Adverse Events were evaluated in company with the causal relationship to Selara.
Number of Participants With Serious Treatment Related Adverse Events.
时间窗: 12 weeks
Serious treatment related adverse events mean those that may lead to death, life-threatening, hospitalization or prolonged hospitalization, a permanent or remarkable disorder/dysfunction, congenital anomaly/congenital deficiency, or other medically significant events or disorder.
次要结局
- Change in Systolic Blood Pressure Over Time.(12 weeks)
- Change in Diastolic Blood Pressure Over Time.(12 weeks)
- Number of Participants That Responded to Selara Treatment.(12 weeks)